Market news

Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The rallies were driven by expanding opportunities tied to biotechnology and artificial intelligence.

FICO, IOVA, SDEV, CCL, MU were among the trending stocks on Tuesday, Sept. 29, 2026.

Iovance Biotherapeutics (NASDAQ:IOVA) saw its share price increase by 31.48 percent on Tuesday to finish at $14.45 apiece after raising its full-year revenue growth guidance by as much as 60 percent, thanks to the strong demand for its cancer treatments. In an updated report on the same day, the company said that it is now […]

Iovance Biotherapeutics, Inc. stock surges as AMTAGVI launch beats expectations; FY26 guidance raised. Click here to read this IOVA update.

Iovance Biotherapeutics (IOVA) stock jumps as the company raises its full-year revenue to a level above the consensus, implying nearly 60% YoY growth. Read more here.

Iovance Biotherapeutics upgrades 2026 revenue guidance to $410 million-$420 million. Key technicals, analyst targets, and Amtagvi demand analyzed.

Gainers Stablecoin Development (AMEX:SDEV) stock increased by 121.6% to $3.48 during Tuesday's regular session. The market value of their outstanding shares is at $42.5 million. Iovance Biotherapeutics

Here are some of the companies making headlines in midday trading.

U.S. stocks mixed as Dow fell 100+ points; CarMax surged 9.7% on strong results, while Iovance, Carnival and others gained.

Iovance raised its 2026 revenue forecast due to strong U.S. demand for Amtagvi and Proleukin cancer therapies.

Iovance Biotherapeutics (NASDAQ:IOVA) raised its full-year 2026 total revenue guidance to between $410 million and $420 million, compared with its previous forecast of $350 million to $370 million. The midpoint of the revised range is $55 million above the midpoint of the previous guidance and represents an increase of approximately 15%.

New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today raised its full year 2026 total revenue gui

An influential investment bank resumed its coverage of the company.

Iovance Biotherapeutics (IOVA) shares have been active after the company reported record second quarter revenue of nearly US$100 million and a 56% margin, alongside broader plans for its tumor infiltrating lymphocyte platform. Iovance Biotherapeutics has seen momentum build quickly, with a 90-day share price return of 162.15% and a year-to-date share price gain of 306.75%. The 1-year total shareholder return of 400% contrasts with a 5-year total shareholder return that remains down...

Iovance Biotherapeutics recently reported record second-quarter results, generating nearly US$100 million in revenue with a 56% margin, while rapidly expanding access to its Amtagvi TIL therapy across more authorized treatment centers and broader payer coverage. At the same time, the company is pushing its TIL platform beyond melanoma into lung, sarcoma, and endometrial cancers, and advancing genetically modified TIL and engineered IL-2 programs that could materially reshape its long-term...

The analyst fair value estimate for Iovance Biotherapeutics has shifted from US$9.33 to US$10.00 per share, reflecting a fresh round of updated models. Recent research points to Amtagvi revenue trends, margin progression, and the potential impact of upcoming data such as IOV-LUN-202 as key reasons behind the new cluster of price targets in the US$10 to US$15 range. Read on to see how these moves fit into the broader analyst narrative and how to track the next set of updates. Analyst Price...

Iovance Biotherapeutics has seen its stock price move sharply in recent years, which puts fresh attention on whether the current valuation lines up with the scale of its sales. For anyone looking at Iovance today, the key issue is how that share price stacks up against the revenue base supporting it. The stock has returned 400.0% over the past year, which raises a direct question about how much sales performance can underpin that kind of move. The business model, focused on developing and...

SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 17, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 179,750 shares of Iovance’s common stock to eighteen ne

Barclays raised Iovance’s price target to $15 from $13 while maintaining an ‘Overweight’ rating, according to The Fly.

SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences: Wells Fargo 21st Annual Healthcare ConferenceFireside Chat: September 10, 2026, at 11:00 a.m. ETBoston, MA H.C. Wainwright 28th Annual Global

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

UBS analyst David Dai raised the firm’s price target on IOVA to $7 from $4 on Thursday while maintaining a Neutral rating.

Does Iovance Biotherapeutics (IOVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Iovance Biotherapeutics, Inc.’s Q2 Amtagvi sales breakout and near-term NSCLC readout could drive upside vs. rivals like IMTX. Click for this IOVA stock update.

Investors responded to clinical progress, improving commercial performance and new growth opportunities.

Why Iovance Biotherapeutics stock is back in focus after Q2 earnings Iovance Biotherapeutics (IOVA) is back on investor radars after its second quarter 2026 earnings. The company reported higher revenue and a reduced net loss, and it reaffirmed full year revenue guidance. The quarter was driven by Amtagvi and Proleukin sales, and by progress across Iovance Biotherapeutics pipeline programs, including new regulatory approvals and Fast Track designations for lifileucel in certain soft tissue...

Motley Fool Press Release.

The healthcare stock is now up more than 130% this year.

Iovance Biotherapeutics Inc (IOVA) reports record Q2 2026 revenue of $99.3 million, driven by strong Amtagvi demand and all-time high gross margins of 56%.

Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic